Mark A. F. Kendall (BE PhD FTSE FRSA FNAI) (born 1972) is an Australian biomedical engineer, inventor, scientist and entrepreneur.
[2] Kendall was formerly the Professor of Biomedical Engineering at the University of Queensland, where he led a team at the Australian Institute for Bioengineering and Nanotechnology[citation needed].
Whilst at Oxford, Kendall was Associate Director of the PowderJect Research Centre for Gene and Drug Delivery[citation needed].
Kendall serves at the co-chair of the $150 million Australian Stem Cell Therapies Mission[3] and on the World Economic Forum Global Future Council on Biotechnology.
[5] The biotech enterprises he has founded or made significant contribution to have generated in the region of $2 billion Aus in value[citation needed].
Kendall founded Vaxxas in 2011 to advance his Nanopatch[15] technology for global impact, securing more than $40 million of investment, in the series A ($15m)[37] and B (in excess of $25m) rounds.